Enfuvirtide

FuzeonImmune/Anti-inf

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeAntiviral

MechanismHIV-1 fusion inhibitor; binds gp41 and prevents viral entry into the cell

EffectsA peptide that works mechanically by blocking viral entry rather than by signalling

Dosing90 mg SC twice daily

Bottom lineStrongest data when used for its labeled indication under clinician guidance.

Batches on filenone

No tested batches on file.

Read with10

VIP ARA-290 Semaglutide Tirzepatide Liraglutide Exenatide Dulaglutide Pramlintide Cagrilintide Retatrutide

Cautions & interactions

Injection-site reactions are near-universal; hypersensitivity reactions; increased bacterial pneumonia risk

No significant CYP-mediated interactions; coordinate within the full antiretroviral regimen.

CV 1 of 5 — No direct cardiovascular signal attributable to the drug itself.